On December 8, 2025, CFO Balaji Gandhi told investors on the Q3 2026 earnings call: "For fiscal year 2027, we expect revenue to be in the range of $545 million to $559 million." Gandhi also stated that the recently acquired AccessOne would "contribute approximately 6.5% of our fiscal 2027 total revenue outlook." On March 30, 2026, the Company issued its Q4 2026 earnings release and reduced FY 2027 revenue guidance to $510-$520 million — a reduction of $35 million to $49 million from the prior range.
The Company attributed the revision to weaker pharmaceutical-marketing commitments and shorter visibility in its Network Solutions segment. Neither risk factor had been referenced in the December 8, 2025 earnings call, where management described "progress" in the selling season for network solutions. The stock fell 21-28% on the revised outlook.
To receive more information, please fill out the form.
